

ISO 20069:2019 (E)

Guidance for assessment and evaluation of changes to drug delivery systems

Contents

	Foreword
	Introduction
1	Scope
2	Normative references
3	Terms, definitions and abbreviated terms
3.1	Terms and definitions
3.2	Abbreviated terms
4	Process
4.1	General
4.1.1	Process framework
4.1.2	Quality and risk management
4.1.3	Relationships within the organization and with suppliers or external organizations
4.2	Phase A — Define and assess
4.2.1	Define change (Figure 1, box 1)
4.2.2	Identify change types (Figure 1, box 2)
4.2.3	Assess impact of change (Figure 1, box 3)
4.2.3.1	Assess drug delivery system performance
4.2.3.2	Assess safety
4.2.3.3	Assess drug delivery system stability
4.2.3.4	Assess drug delivery system/medicinal product compatibility
4.2.3.5	Assess manufacturing processes
4.2.3.6	Assess usability
4.2.3.7	Assess software
4.2.3.8	Assess clinical data set
4.2.3.9	Assess regulatory compliance
4.3	Phase B — Execute activities
4.3.1	Plan (Figure 1, box 4)
4.3.2	Execute (Figure 1, box 5)
4.4	Phase C — Final evaluation
4.4.1	General
4.4.2	Review data (Figure 1, box 6)
4.4.3	Evaluate clinical comparability (Figure 1, box 7)
4.4.4	Decision to proceed with change (Figure 1, box 8)
Annex A	(informative) Templates
Annex B	(informative) Example of completed templates for assessing and evaluating a change
B.1	Example for assessing and evaluating a component colour change
B.2	Example for assessing needle-free injector change
B.3	Example of assessing a primary container material change
B.4	Example for assessing a medicinal product formulation change